Misha V. Blagosklonny graduated with an MD and PhD from First Pavlov State Medical
University of St. Petersburg, Russia. Dr. Mikhail V. Blagosklonny has then
Immigrated to America, where he was
Awarded the prestigious Fogarty Fellowship from the National Institutes of Health.
During his fellowship in Leonard Neckers’ lab at the National
Cancer Institute (NCI), he was a co-author of 18 publications on
Diversified biomedical topics, suchas targeting
HSP90, p53, Bcl2, Erb2, and Raf-1. He also was the last author on a clinical phase I/II
Trial paper.
 
After authoring seven papers during a brief yet fruitful
Senior research fellowship in the El-Deiry Cancer Research Lab at the University of Pennsylvania,
Dr. Blagosklonny returned to NCI to cooperate with Tito Fojo. Together, they
Published 26 papers. Moreover, Dr. Mikhail Blagosklonny published a
Lot of experimental research articles and theoretical papers as sole
Writer. These sole-author publications
Highlighted two crucial themes.
The first of those explained selectively killing cancer
Cells with deregulated cell cycle or drug resistance by
Verifying their resistance. The results and underlying
Notion were so revolutionary that they were incorrectly cited by
Other scientists as “reversal of resistance, ” even though the paper was
Named, “Exploiting of drug resistance instead of its reversal. ” One big
Supporter of this concept was the world-famous scientist Arthur Pardee, with whom Dr.
Blagosklonny co-authored a joint paper in 2001.
 
The second theme throughout Dr. Blagosklonny’s sole-author publications
Is a research methodology to create knowledge via
Uniting several facts together from seemingly unrelated fields.
This results in new concepts containing testable predictions, which in
Turn can be “tested” via analyzing the literature further. Likewise, the
Concept was co-authored by Arthur Pardee in a 2002 publication in Nature. The
First success of the new research methodology was the description of the feedback
Regulation of p53, as confirmed by the discovery of mdm2/p53 loop; and the
Explanation why mutant p53 is always overexpressed, published in 1997. The most
Crucial outcome revealed by Dr.
Blagosklonny’s research methodology is the hyperfunction (or quasi-programmed)
Theory of aging and the revelation of rapamycin as an exclusively well-tolerated
Anti-aging medication, published in 2006. As mentioned in Scientific American,
Michael Hall, who discovered mTOR in 1991, gives Dr. Blagosklonny credit for
“connecting dots that others do not even see. ”
 
In 2002, Dr. Blagosklonny became associate professor of medicine at New York Medical College.
He decided to accept responsibilities as a senior scientist at Ordway
Research Institute in Albany, New York, in 2005, prior to receiving another
Position at Roswell Park Cancer Institute as professor of oncology in 2009.
 
Since coming to Roswell Park Comprehensive Cancer Center in 2009, Dr. Blagosklonny
Has studied the prevention of cancer (an age-related disease) by
Inhibiting organism aging — in other words, “preventing cancer
By remainng young. ” His laboratory closely collaborated with
Andrei Gudkov’s and performed research on the suppression of
Cellular senescence, namely suppression of cellular conversion from healthy quiescence to
Permanent senescence. This led to the discovery of additional anti-aging
Medicines beyond rapamycin. The cell culture studies were
Complemented by studies in mice, including a few models like
Standard and aging mice, p53-deficient mice, and mice on a high-fat diet.
 
Dr. Mikhail Blagosklonny has also published extensively on the stoppage of cellular
Senescence by rapamycin and other mTOR inhibitors, life
Prolongation and cancer cure in mice, and combinations of anti-
Aging medications to be used in humans. A
Rapamycin-based combination of seven clinically available medications has
Been named the “Koschei Formula” and is now used for the treatment of aging in patients
At the Alan Green Clinic in Little Neck, New York.